ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Rating of “Buy” from Brokerages

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been given a consensus rating of “Buy” by the four research firms that are covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $80.00.

A number of research firms have commented on ANIP. HC Wainwright raised their target price on ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a “buy” rating in a report on Monday, March 4th. Truist Financial increased their price objective on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Capital One Financial assumed coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 15th. They set an “overweight” rating and a $80.00 target price for the company. Finally, Guggenheim reiterated a “buy” rating and issued a $77.00 price target on shares of ANI Pharmaceuticals in a research report on Tuesday, April 23rd.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock opened at $67.25 on Friday. ANI Pharmaceuticals has a one year low of $37.64 and a one year high of $70.81. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.81 and a current ratio of 3.57. The business has a fifty day moving average of $66.58 and a two-hundred day moving average of $59.16. The company has a market cap of $1.42 billion, a P/E ratio of 80.06 and a beta of 0.80.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. The company had revenue of $131.65 million during the quarter, compared to the consensus estimate of $123.02 million. As a group, analysts predict that ANI Pharmaceuticals will post 3.55 earnings per share for the current fiscal year.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, SVP Chad Gassert sold 20,000 shares of ANI Pharmaceuticals stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $67.25, for a total transaction of $1,345,000.00. Following the completion of the sale, the senior vice president now directly owns 253,226 shares in the company, valued at $17,029,448.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, COO Muthusamy Shanmugam sold 16,809 shares of the company’s stock in a transaction on Friday, April 19th. The stock was sold at an average price of $65.17, for a total value of $1,095,442.53. Following the completion of the transaction, the chief operating officer now directly owns 782,620 shares in the company, valued at $51,003,345.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Chad Gassert sold 20,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $67.25, for a total value of $1,345,000.00. Following the completion of the sale, the senior vice president now directly owns 253,226 shares in the company, valued at $17,029,448.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 176,803 shares of company stock worth $11,695,866. Corporate insiders own 12.70% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. New York State Teachers Retirement System boosted its holdings in shares of ANI Pharmaceuticals by 0.9% in the 3rd quarter. New York State Teachers Retirement System now owns 22,180 shares of the specialty pharmaceutical company’s stock valued at $1,288,000 after purchasing an additional 200 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in ANI Pharmaceuticals by 93.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 513 shares of the specialty pharmaceutical company’s stock valued at $30,000 after acquiring an additional 248 shares during the last quarter. Oregon Public Employees Retirement Fund grew its position in ANI Pharmaceuticals by 9.2% during the third quarter. Oregon Public Employees Retirement Fund now owns 4,754 shares of the specialty pharmaceutical company’s stock valued at $276,000 after acquiring an additional 400 shares during the period. Arizona State Retirement System increased its stake in ANI Pharmaceuticals by 9.9% during the third quarter. Arizona State Retirement System now owns 4,589 shares of the specialty pharmaceutical company’s stock worth $266,000 after acquiring an additional 415 shares during the last quarter. Finally, Maryland State Retirement & Pension System raised its holdings in shares of ANI Pharmaceuticals by 8.8% in the 3rd quarter. Maryland State Retirement & Pension System now owns 5,901 shares of the specialty pharmaceutical company’s stock worth $343,000 after purchasing an additional 476 shares during the period. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.